Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Biohaven develops and sells medicines for brain and nerve diseases, immune disorders, and cancer.
Biohaven is a biotech company that makes medicines for the brain and nervous system, along with a smaller push into immune and cancer drugs. Its job is to take a chemical that might treat a disease, test it in people, get it approved by regulators, and sell it. The customers are patients, but the people who actually pay are insurance companies and government health programs, which reimburse for prescriptions.
Its lead product is a nasal spray called Nurtec for migraine. The drug uses a chemical that blocks a pain-signaling protein called CGRP, and the nasal form is meant for fast relief when a migraine hits. Biohaven sells it in the US and has been expanding into other countries. It also sells a related drug, and it inherited a royalty stream from a migraine drug it developed earlier and sold to Pfizer — a deal that gave Biohaven cash and a continuing slice of that drug's sales. Beyond migraine, Biohaven has a pipeline of experimental drugs for conditions like obsessive-compulsive disorder, epilepsy, and a rare nerve-wasting disease. Most of these are still in testing, so the company's future depends on whether they work and get approved. That makes it a risky, science-driven business: one good trial result can lift the stock, and one failure can sink it.
The business is not yet solidly profitable, because it spends heavily on research and on launching Nurtec. Its cash comes from product sales and the Pfizer royalty, and it uses that money to fund trials rather than pay dividends. The main competition is other migraine drugs from companies like AbbVie and Eli Lilly. Biohaven's bet is that a fast-acting nasal spray, plus a deep pipeline of brain-disease drugs, gives it an edge. Whether that bet pays off depends on the science.
Saved answer · last researched 16 Nov 2026